Introduction
============

The *E2F* transcription factors (*E2Fs*), which were discovered almost 30 years ago, have been confirmed to play significant roles in cell proliferation, differentiation, and apoptosis.[@b1-cmar-10-3521] It is known that there are eight *E2F* family member genes so far, named *E2F1*--*E2F8* in the order of discovery. The *E2Fs* came to the forefront of cancer research when they were found to be associated with and regulated by the RB protein, the product of gene mutation in retinoblastoma.[@b2-cmar-10-3521] Cancer-related proliferative roles of *E2Fs* have been found in many kinds of human cancer, including breast carcinoma (BC). It was found that they regulated tumor development and metastasis in animal models of BC.[@b2-cmar-10-3521],[@b3-cmar-10-3521] These eight *E2Fs*, however, are supposed to have some specific functions and overlapping roles according to current studies.[@b4-cmar-10-3521]

BC, the most common malignant tumor among women in both developed and developing countries, remains one of the leading causes of cancer death among women worldwide.[@b5-cmar-10-3521] BC is supposed to have diverse characteristics in pathology and molecular biology. BC subtypes defined by immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 provide prognostic values of BC patients.[@b6-cmar-10-3521] In this molecular classification system, triple-negative BC (TNBC) has the worst overall survival (OS) and disease-free survival (DFS),[@b6-cmar-10-3521] and the *E2Fs* have been implicated in regulation of TNBC.[@b7-cmar-10-3521] Complex genetic mechanisms regulate and control the cell cycle in cancers, including amplification, mutation, and overexpression of the genes encoding the core components in the cell cycle.[@b8-cmar-10-3521] These components include the cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors, and *RB1*, all of which contribute to activation of the downstream *E2Fs*, and activation of *E2Fs* in turn causes unrestricted cell proliferation and divisions.[@b8-cmar-10-3521] Mutations of the *RB1* gene or components regulating the CDK-RB-*E2F* pathway have been identified in nearly all human malignant tumors, including BC.[@b8-cmar-10-3521]

The *E2Fs*, as mentioned before, are supposed to have complex and distinct roles in human BC. Several reports have discovered that amplification of the *E2F1* or *E2F3* gene locus and overexpression of *E2F1* or *E2F3* were frequent genetic events in many human malignancies, whereas large chromosomal deletions of regions including the *E2F1*, *E2F2* or *E2F3* genes have been detected in some cases.[@b9-cmar-10-3521] The conclusions of current studies on the role of *E2F4* are controversial regarding whether it was a suppressor or an activator of carcinogenesis. *E2F4* seemed to be able to function as a tumor suppressor or an oncogene through regulating alternative sets of genes in different tissues.[@b9-cmar-10-3521] An increased gene copy number of *E2F5* was detected in two independent cohorts of BC patients.[@b10-cmar-10-3521],[@b11-cmar-10-3521] Evidence from several studies found that *E2F6* negatively regulated *BRCA1* in human cancer cells, functioning as a repressive transcription factor in a histone methyltransferase independent manner on target promoters.[@b12-cmar-10-3521],[@b13-cmar-10-3521] For BC patients receiving tamoxifen treatment, high expression level of *E2F7* was associated with elevated risk of relapse and poor prognosis.[@b14-cmar-10-3521] Up-regulation of *E2F8* was reported to promote cell proliferation and tumorigenicity in BC by modulating the G1/S phase transition.[@b15-cmar-10-3521] However, due to limited studies at present, the expression patterns, functions, and prognostic values of the *E2Fs* in human BC have not been clearly elucidated.

Microarray technology, which has developed rapidly during the past few years, has revolutionized DNA and RNA research and has become essential technology for biomedical research.[@b16-cmar-10-3521] Based on comprehensive analysis of gene expression data and survival data published online, we performed this study to clarify and determine the distinct patterns of expression and significance for survival prognosis of eight *E2Fs* in BC patients.

Materials and methods
=====================

Ethics statement
----------------

This study was conducted in accordance with the principles of the Declaration of Helsinki, and with the approval from the academic committee of Sun Yat-sen University Cancer Center. All data were obtained from published online research, which undoubtedly contained informed consent.

ONCOMINE
--------

ONCOMINE, a cancer microarray database and web-based data-mining platform,[@b17-cmar-10-3521] was applied to analyze the mRNA levels of *E2Fs* in BC. We searched ONCOMINE ([www.oncomine.org](http://www.oncomine.org)) for the fold changes of *E2Fs* in BC using the filters of differential analysis (cancer vs normal), cancer type (breast cancer), sample type (clinical specimen), data type (mRNA), and gene (*E2F1*, *E2F2*, *E2F3*, *E2F4*, *E2F5*, *E2F6*, *E2F7*, or *E2F8*). The comparisons of mRNA levels of *E2Fs* in BC and normal tissues in each individual dataset were conducted using the Student's *t*-test. We then conducted the meta-analysis of differential expression of *E2Fs* in BC vs normal tissues. Random-effects models were employed in the meta-analysis according to the method previously described elsewhere.[@b18-cmar-10-3521]

The Breast Cancer Gene-Expression Miner v4.1
--------------------------------------------

The Breast Cancer Gene-Expression Miner v4.1 (bcGenEx-Miner v4.1) is a statistical mining tool of 36 published annotated genomic datasets (total of 5,861 patients) and has three statistical analysis functions, as listed in the following paragraphs.[@b19-cmar-10-3521],[@b20-cmar-10-3521] The expression module permitted comparisons of expressions of candidate genes according to several clinical criteria, such as age, nodal status, ER status, PR status, HER2 status, and so on. The prognostic module evaluated the prognostic values of candidate genes in human BC and the correlation module permitted analysis of the correlations between candidate genes.

The cBioPortal for Cancer Genomics
----------------------------------

The cBioPortal for Cancer Genomics provides visualization, analysis, and downloading of large-scale cancer genomics datasets.[@b21-cmar-10-3521],[@b22-cmar-10-3521] The breast cancer dataset (METABRIC, Nature 2012),[@b23-cmar-10-3521] which contains data, including histopathological data of 2,509 BC patients, was chosen for analyses of *E2Fs* using the cBioPortal for Cancer Genomics ([www.cbioportal.org](http://www.cbioportal.org)). Selected genomic profiles included mutations, copy-number variance from GISTIC, and mRNA expression z scores (Illumina Human v3 micro- array) with a *z* score threshold of ±2.0. OS was calculated with the Kaplan--Meier survival curve according to the instruction on the website.

The Kaplan--Meier Plotter
-------------------------

The Kaplan--Meier Plotter ([www.cbioportal.org](http://www.cbioportal.org)),[@b24-cmar-10-3521] which collected miRNA expression data and survival data of a total of 5,143 BC patients from gene expression omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>), The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov/>), European Genome-phenome Archive (EGA) (<https://ega.crg.eu/>), and PubMed (<http://www.pubmed.com>),[@b25-cmar-10-3521],[@b26-cmar-10-3521] was used to explore the prognostic values of mRNA levels of *E2Fs* in BC. BC patients were divided into two groups by the median mRNA expression level (high expression vs low expression) in order to analyze the OS and relapse-free survival (RFS) with Kaplan--Meier plots, in which the number-at-risk was listed. Only the JetSet best probe set of *E2Fs* was selected for our analysis.[@b27-cmar-10-3521] The HR with 95% CI and the log-rank *P*-value was calculated in each Kaplan--Meier survival plot and the cutoff of log-rank *P*-value was defined as 0.05.

Results
=======

The transcription levels of *E2Fs* in BC compared with that in normal tissues
-----------------------------------------------------------------------------

A total of 13 datasets containing 3,555 samples were included in this study, of which the largest two are the Curtis dataset (2,136 samples) and TCGA dataset (593 samples). The Curtis dataset collected breast cancer specimens from tumor banks in the UK and Canada,[@b28-cmar-10-3521] while TCGA dataset was generated by the National Cancer Institute (NCI) in the USA. Through conducting meta-analysis based on the ONCOMINE data bases, we compared the transcription levels of eight *E2Fs* in BC and normal tissues ([Tables S1--S8](https://pan.baidu.com/s/1Fhw1znDASi0qMgG2ienc_w%23list/path%3D%252F)) We found that the mRNA expression levels of *E2F1*, *E2F2*, *E2F3*, *E2F5*, *E2F6*, *E2F7*, and *E2F8* were significantly higher in BC tissues, with fold changes of 1.63, 2.07, 1.53, 1.61, 1.21, 2.27, and 2.05, respectively ([Table 1](#t1-cmar-10-3521){ref-type="table"}). However, there was no significant difference between the transcription levels of *E2F4* in BC and normal tissues (fold change =1.13, 95% CI: 0.87--1.40).

The mRNA levels of *E2Fs* are correlated with clinical and molecular features of BC patients
--------------------------------------------------------------------------------------------

The Welch's tests, along with Dunnett-Tukey-Kramer's tests for pairwise comparison when appropriate, were performed to compare the mRNA levels of *E2Fs* between groups of patients divided according to different clinical and molecular criteria in the bcGenExMiner v4.1. For the criterion of age, it was found that no significant difference existed between ≤51 years old and \>51 years old groups of *E2F1*, *E2F4*, *E2F7*, and *E2F8*, whereas downregulated expression of *E2F2*, *E2F3*, *E2F5*, and *E2F6* in the older group was found ([Table 2](#t2-cmar-10-3521){ref-type="table"}). BC patients with positive nodal status showed higher mRNA level of *E2F5* than negative nodal patients ([Table 2](#t2-cmar-10-3521){ref-type="table"}).

Higher Scarff Bloom & Richardson (SBR) grade status was found to be correlated with higher mRNA levels of all *E2Fs* ([Figure 1](#f1-cmar-10-3521){ref-type="fig"}). For *E2F4* and *E2F6*, although a significant difference was detected in the Welch's test, the group comparison between SBR1 and SBR2 by Dunnett-Tukey-Kramer's test of both did not show a significant difference (the cutoff value of *P* is 0.05) ([Table S9](https://pan.baidu.com/s/1Fhw1znDASi0qMgG2ienc_w%23list/path%3D%252F)).

We found that ER status was negatively associated with mRNA levels of *E2Fs* except for *E2F6*, whereas PR status was negatively associated with mRNA levels of *E2Fs* except for *E2F5*. In HER2-positive groups of BC patients, the transcription levels of *E2F1*, *E2F3*, *E2F7*, and *E2F8* were significantly up-regulated compared with HER2-negative groups. As mentioned before, TNBC is a special type of BC with negative ER, PR, and HER2, and has the worst clinical outcome. The mRNA levels of *E2Fs*, except for *E2F4* and *E2F6*, were found to be significantly higher in TNBC patients ([Table 2](#t2-cmar-10-3521){ref-type="table"}).

BC patients with alterations of *E2Fs* have poorer OS
-----------------------------------------------------

Among the overall 2,509 patients with breast invasive carcinoma in the selected dataset, 1,120 (44.6%) were detected to have alterations of *E2Fs* ([Figure 2A](#f2-cmar-10-3521){ref-type="fig"}). *E2F5* was altered in 22% of BC patients in this dataset. BC patients with alterations of *E2Fs* were found to have significantly poorer OS according to analyses by log-rank tests in the Kaplan--Meier survival plots (*P*=0.0249) ([Figure 2B](#f2-cmar-10-3521){ref-type="fig"}).

Higher mRNA levels of *E2F1*, *E2F3*, and *E2F8* were associated with poorer OS and RFS of BC patients
------------------------------------------------------------------------------------------------------

It was found that mRNA levels of *E2F1*, *E2F3*, and *E2F8* were significantly correlated with OS and RFS in all BC patients (*P*\<0.05) ([Figures 3](#f3-cmar-10-3521){ref-type="fig"} and [4](#f4-cmar-10-3521){ref-type="fig"}), through analyses by log-rank tests in the Kaplan--Meier survival plots. Higher mRNA levels of *E2F1*, *E2F3*, and *E2F8* predicted poorer OS and RFS in BC patients. In contrast, BC patients with higher mRNA levels of *E2F4* were found to have better RFS. Additionally, transcription levels of *E2F7* were negatively associated with RFS but not OS in BC patients.

Discussion
==========

The *E2Fs* were involved in BC development and metastasis, and demonstrated prognostic values according to currently available limited studies. However, the multifaceted roles of *E2Fs* in the development, metastasis, and prognostication of BC remain to be clarified. As far as we know, this is the first study that systematically analyzed the mRNA expression levels and prognostic values of the eight *E2Fs* in human BC.

*E2F1*, the first member of the family of *E2Fs*, was proven to initiate and maintain tumors originating from distinct tissues in multiple mouse models.[@b29-cmar-10-3521] However, some studies demonstrated that they induced cell apoptosis and resulted in inhibition of tumor growth in some specific tissue types, such as the skin.[@b29-cmar-10-3521] As for BC, Wu et al found that *E2F1* played an oncogenic role in *ErbB2*- or *Myc*-triggered mam mary tumorigenesis.[@b30-cmar-10-3521] Moreover, the low transcription level of *E2F1* was reported as a strong determinant of favorable outcome for BC patients.[@b31-cmar-10-3521] In this study, we found that the mRNA level of *E2F1* was significantly up-regulated in BC. Higher mRNA level of *E2F1* was associated with higher SBR grade and TNBC, which predicted higher degree of malignancy, higher incidence of recurrence and metastasis, and worse clinical outcomes. In survival analysis, BC patients with higher mRNA level of *E2F1* were found to have poorer OS and RFS. We thus suppose *E2F1* as a target for precision therapy of BC patients, and a previous study in cell lines found that MIR372 inhibited proliferation and induced apoptosis in BC cells by directly targeting *E2F1*.[@b32-cmar-10-3521]

Significant reductions in tumor incidence, the metastatic capacity of the tumor and the number of circulating tumor cells in animals with *E2F2* knockout background were found in numerous studies.[@b2-cmar-10-3521],[@b33-cmar-10-3521] *E2F2* loss resulted in increased metastasis of BC, potentially functioning through a PTPRD-dependent mechanism.[@b22-cmar-10-3521] Interestingly, on the contrary, Wu et al noted a tumor suppressor role of *E2F2* in *Myc*-mediated mammary tumorigenesis.[@b30-cmar-10-3521] The mRNA level of *E2F2* was found to be significantly higher in BC, especially in TNBC, and it was positively associated with the SBR grade as *E2F1*. However, unlike *E2F1*, mRNA expression level of *E2F2* did not have prognostic values for OS or RFS of BC patients. Nguyen-Vu et al reported that LXR ligand treatment downregulated transcription level of *E2F2* and resulted in significant disruption of cell proliferation in ER-positive BC.[@b34-cmar-10-3521] This finding supported that *E2F2* might also be a potential treatment target for BC. Considering the small number of studies focused on functions of *E2F* in BC, more work needs to be carried out in future.

The oncogenic activity of *E2F3* has been observed in *ErbB2*- or *Myc*-triggered mammary tumorigenesis.[@b30-cmar-10-3521] Fujiwara et al noted a significant reduction in tumor incidence with the loss of *E2F3*,[@b33-cmar-10-3521] whereas Lee et al found that *E2F3* silencing inhibited mammary tumor growth through reducing the percentage of cells undergoing mitosis.[@b35-cmar-10-3521] An in vitro study demonstrated that *E2F3* was a diagnostic and potential therapeutic target in BC.[@b36-cmar-10-3521] In this study, the mRNA level of *E2F3* was found to be significantly higher in BC. Higher mRNA level of *E2F3* was associated with higher SBR grade and TNBC. Survival analysis revealed that higher mRNA levels of *E2F3* predicted poorer OS and RFS in BC patients, and we thus suppose *E2F3* as another therapeutic target for BC patients. A previous study found that metformin reduced the incidence of breast cancer and metastasis by increasing miR-26a expression, which downregulated the expression level of *E2F3*.[@b37-cmar-10-3521] Another in vitro study reported that T-VISA-miR-34a induced expression of miR-34a, and dramatically suppressed growth, migration, and invasion of breast cancer cells by downregulating the protein expression levels of target genes including *E2F3*.[@b38-cmar-10-3521] Vimala et al found that siRNA for *E2F3* facilitated the silencing of *E2F3* overexpression and "fought against" BC in cell lines.[@b36-cmar-10-3521] Results of these studies are consistent with our assumption.

It was reported that *E2F4* had an oncogenic role rather than a tumor suppressor role in breast carcinogenesis, and expression of *E2F4* in invasive BC was associated with poor prognosis.[@b39-cmar-10-3521] Although there was no significant up-regulation or downregulation of *E2F4* expression level in BC, BC patients with higher mRNA levels of *E2F4* were found to have significantly better RFS. We thus supposed that *E2F4* was a potential prognostic marker for better survival of BC patients. Considering the currently available little evidence and the unavoidable limitations of this study, further research needs to be performed to investigate the role of *E2F4* in BC.

Polanowska et al found that *E2F5* was oncogenic in primary rodent cells and was amplified in human BC,[@b10-cmar-10-3521] whereas Umemura et al found that *E2F5*-positive subtype of BC was associated with a basal phenotype, TNBC, and worse clinical outcome.[@b11-cmar-10-3521] In this study, it was found that the mRNA level of *E2F5* was significantly higher in BC. Higher mRNA level of *E2F5* was correlated with higher SBR grade and TNBC. BC patients with positive nodal status showed significantly higher mRNA level of *E2F5* than negative nodal patients. This finding supported that *E2F5* might play a role in lymph node metastasis of BC patients. Through targeting *E2F5* with miR-154 in cell lines, the growth and invasion of breast cancer cells were inhibited.[@b40-cmar-10-3521] However, mRNA expression levels of *E2F5* did not have prognostic values in BC patients according to our study.

Several current studies found that *E2F6* negatively regulated *BRCA1* in BC.[@b12-cmar-10-3521],[@b13-cmar-10-3521] The mRNA level of *E2F6* was found to be significantly higher in BC, and higher mRNA level was found in higher SBR grade of BC patients, which indicated worse clinical outcomes. However, no significant difference of OS or RFS was found between BC patients with high and low mRNA level of *E2F6*. As little research has focused on *E2F6* so far, the underlying role of *E2F6* in BC needs more investigation.

*E2F7* and *E2F8* were both supposed to promote tumorigenicity in breast cancer according to currently available limited studies.[@b14-cmar-10-3521],[@b15-cmar-10-3521] We found that both of their transcription levels were significantly higher in BC. BC patients with higher SBR grade and TNBC patients had higher mRNA levels of *E2F7* and *E2F8*. Not surprisingly, the transcription levels of *E2F7* and *E2F8* were negatively associated with RFS of BC patients. Higher *E2F8* expression level also predicted worse OS of BC patients. These results indicate that *E2F7* and *E2F8* are both potential new targets for individualized treatments of BC patients, and further studies need to be performed to explore their potential values.

We also found that alterations of *E2Fs* were frequent genetic events in BC patients and BC patients with alterations of *E2Fs* appeared to have significantly poorer OS, although the underlying mechanism is still unclear.

Conclusion
==========

We performed comprehensive analyses on the expressions and prognostic values of the eight *E2Fs* in BC in this study, for the first time, to provide a better understanding of the diversity of BC regarding various aspects including clinical, histopathological, and biomolecular characteristics. Our results indicate that *E2F1*, *E2F3*, *E2F7*, and *E2F8* are potential targets for individualized treatment of BC patients, whereas *E2F4* is a potential prognostic marker for better survival of BC patients.
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![The relationship between mRNA levels of *E2Fs* and SBR grade.\
**Notes:** (**A**) *E2F1* (204947_at). (**B**) *E2F2* (228361_at). (**C**) *E2F3* (203693_s\_at). (**D**) *E2F4* (202248_at). (**E**) *E2F5* (221586_s\_at). (**F**) *E2F6* (203957_at). (**G**) *E2F7* (228033_at). (**H**) *E2F8* (219990_at).\
**Abbreviations:** *E2Fs*, *E2F* transcription factors; SBR, Scarff Bloom & Richardson.](cmar-10-3521Fig1){#f1-cmar-10-3521}

![Analysis of *E2Fs*' alterations in breast invasive carcinoma (using cBioPortal for Cancer Genomics[@b21-cmar-10-3521],[@b22-cmar-10-3521]).\
**Notes:** (**A**) The Kaplan--Meier plot comparing overall survival of breast carcinoma patients with *E2F* alterations (n=1,120) and without *E2F* alternations (n=1,389). (**B**) Oncoprint in cBioPortal represented the proportion and distribution of cases with *E2F* alterations. The figure was cropped on the right to exclude cases without alterations.\
**Abbreviation:** *E2Fs*, *E2F* transcription factors.](cmar-10-3521Fig2){#f2-cmar-10-3521}

###### 

The prognostic value of mRNA levels of *E2Fs* in BC patients (OS in Kaplan--Meier Plotter).

**Notes:** (**A**) *E2F1* (204947_at). (**B**) *E2F2* (228361_at). (**C**) *E2F3* (203693_s\_at). (**D**) *E2F4* (202248_at). (**E**) *E2F5* (221586_s\_at). **(F**) *E2F6* (203957_at). (**G**) *E2F7* (228033_at). (**H**) *E2F8* (219990_at).

**Abbreviations:** *E2Fs*, E2F transcription factors; BC, breast carcinoma; OS, overall survival.
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###### 

The prognostic value of mRNA levels of *E2Fs* in BC patients (RFS in Kaplan--Meier Plotter).

**Notes:** (**A**) *E2F1* (204947_at). (**B**) *E2F2* (228361_at). (**C**) *E2F3* (203693_s\_at). **(D**) *E2F4* (202248_at). (**E**) *E2F5* (221586_s\_at). (**F**) *E2F6* (203957_at). (**G**) *E2F7* (228033_at). (**H**) *E2F8* (219990_at).

**Abbreviations:** *E2Fs*, E2F transcription factors; BC, breast carcinoma; RFS, relapse-free survival.
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###### 

Results of meta-analysis of differential expression of *E2Fs* in BC vs normal tissues (ONCOMINE)

  *E2Fs*       Datasets                                                                                                       Number of datasets   Fold change (95% CI)
  ------------ -------------------------------------------------------------------------------------------------------------- -------------------- ----------------------
  ***E2F1***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Sorlie; Zhao; Perou; Sorlie 2; Ma 4;                            13                   1.63 (1.32--1.94)
               Karnoub; Radvanyi; Finak                                                                                                            
  ***E2F2***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Zhao; Ma 4; Karnoub; Radvanyi; Finak                            10                   2.07 (1.75--2.38)
  ***E2F3***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Sorlie; Zhao; Perou; Sorlie 2; Karnoub; Finak                   11                   1.53 (1.39--1.67)
  ***E2F4***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Sorlie; Zhao; Perou; Sorlie 2; Ma 4; Karnoub; Finak             12                   1.13 (0.87--1.40)
  ***E2F5***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Sorlie; Zhao; Perou; Sorlie 2; Ma 4; Karnoub; Radvanyi; Finak   13                   1.61 (1.49--1.73)
  ***E2F6***   TCGA; Gluck; Curtis; Zhao; Ma 4; Radvanyi; Finak                                                               7                    1.21 (1.01--1.40)
  ***E2F7***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Ma 4; Karnoub; Radvanyi                                         8                    2.27 (1.82--2.71)
  ***E2F8***   Turashvili; Richardson 2; TCGA; Gluck; Curtis; Zhao; Ma 4; Karnoub; Radvanyi                                   9                    2.05 (1.55--2.55)

**Abbreviations:** *E2Fs*, *E2F* transcription factors; BC, breast carcinoma; TCGA, The Cancer Genome Atlas.

###### 

The correlation between mRNA levels of *E2Fs* and clinical and molecular criteria of BC patients

  Criteria                        *E2F1*   *E2F2*   *E2F3*     *E2F4*   *E2F5*     *E2F6*   *E2F7*     *E2F8*                                                               
  ------------------------------- -------- -------- ---------- -------- ---------- -------- ---------- -------- -------- ---- ---------- ---- -------- ---- ---------- ---- ----------
  **Age**                                                                                                                                                                   
  ≤51                             1,361    --       0.9623     --       0.0284     --       \<0.0001   --       0.5265   --   0.0377     --   0.0004   --   0.8497     --   0.3461
  \>51                            2,142    --                  ↓                   ↓                   --                ↓               ↓             --              --   
  **Nodal status**                                                                                                                                                          
  −                               2,447    --       0.4376     --       0.1055     --       0.7359     --       0.2055   --   0.0246     --   0.8244   --   0.1139     --   0.1536
  \+                              1,509    --                  --                  --                  --                ↑               --            --              --   
  **ER (IHC)**                                                                                                                                                              
  −                               1,525    --       \<0.0001   --       \<0.0001   --       \<0.0001   --       0.0001   --   \<0.0001   --   0.4174   --   \<0.0001   --   \<0.0001
  \+                              3,923    ↓                   ↓                   ↓                   ↓                 ↓               --            ↓               ↓    
  **PR (IHC)**                                                                                                                                                              
  −                               946      --       \<0.0001   --       \<0.0001   --       \<0.0001   --       0.0097   --   0.0919     --   0.0282   --   0.0002     --   \<0.0001
  \+                              1,439    ↓                   ↓                   ↓                   ↓                 --              ↓             ↓               ↓    
  **HER2 (IHC)**                                                                                                                                                            
  −                               1,409    --       0.0083     --       0.3372     --       0.0293     --       0.8335   --   0.6897     --   0.9495   --   0.0012     --   \<0.0001
  \+                              201      ↑                   --                  ↑                   --                --              --            ↑               ↑    
  **Triple-negative BC (TNBC)**                                                                                                                                             
  Not                             4,099    --       \<0.0001   --       \<0.0001   --       \<0.0001   --       0.9164   --   0.0007     --   0.8832   --   0.0251     --   \<0.0001
  TNBC                            374      ↑                   ↑                   ↑                   --                ↑               --            ↑                    

**Note:**

The number of patients was based on the group of *E2F1* and the exact number of patients in other groups may be a little different.

**Abbreviations:** *E2Fs*, *E2F* transcription factors; BC, breast carcinoma; ER, estrogen receptor; IHC, immunohistochemistry; PR, progesterone receptor.
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